Our recent studies have shown that inactivation of FoxM1, and its target genes, by DIM could enhance the therapeutic efficacy of Taxotere in breast and prostate cancer cells [19] suggesting that DIM in combination with Herceptin could be useful to upregulate miR-200 and down-regulate FoxM1 which should help to develop therapeutic strategies for the prevention and/or treatment of breast cancer. This evidence concerns the gene FOXM1 and Familial prostate cancer.